EANO Meeting - Friday, October 17, 2025
Note that the programme is subject to change and will be continuously updated.
All times below refer to Central European Summer Time (CEST).
08:00-09:00 hrs
Chairs: tbc
ME01.1 Molecular landscape and identification of patient at risk
Amanda Fitzpatrick, United Kingdom
ME01.2 Immunological crosstalk with metastasis at the meninges
Jan Remsik, Belgium
ME01.3 Current treatments and assessment of response to treatments
Emilie Le Rhun, Switzerland
Chairs: tbc
JS02.1 Fibrous Solitary Tumor
Alicia Tosoni, Italy
JS02.2 Intracranial germ cell tumors
tbc
JS02.3 Tuberous sclerosis
Angelika Mühlebner, Netherlands
Chairs: tbc
ME02.1 Neuro-Oncology Journal
Susan Chang, United States
ME02.2 Neuro-Oncology Advances Journal
Gelareh Zadeh, Canada
ME02.3 Neuro-Oncology Practice Journal
Martin Taphoorn, Netherlands
09:00-09:15 hrs | BREAK
09:15-10:45 hrs
Chairs: tbc
JS03.1 Modern PET imaging to guide treatment decisions
Jan-Michael Werner, Germany
JS03.2 Theranostics 101 – Essential basics
Nelleke Tolboom, Netherlands
JS03.3 Theranostics potentials in Neuro-Oncology
tbc
Chairs: tbc
KS01.1 Why immunotherapy has a future in glioblastoma?
Michael Platten, Germany
KS01.2 The value to measuring Immune Cell Infiltration and other immune corelates
Robert Prins, United States
KS01.3 What can we learn from molecular and spatial profiling of glioblastoma
Pim French, Netherlands
KS01.4 AllergoOncology: Unraveling the Glioma-Allergy Connection from Epidemiology to Experimental Models
Aurélie Poli, Luxembourg
Chairs: tbc
OS01.1 Long-term side effects on vascular and endocrine functions
Dylan Ryan, United States
OS01.2 Long-Term Experiences of Life Situations in Patients with Low-Grade Glioma
Ben Rimmer, United Kingdom
OS01.3 Quality of life in patients with slow growing tumors
Florien Boele, United Kingdom
OS01.4 Rehabilitation from a long-term perspective
tbc
Chairs: tbc
Introductory talk: Why storytelling matters in neuro-oncology
Susan Short, United Kingdom
Table 1: Storytelling in publications - Basic/Translational science
Manuel Valiente, Spain
tbc
Table 2: Storytelling in publications - Clinical science
Matthias Preusser, Austria
tbc
Table 3: Storytelling in grant and fellowship applications
Leila Akkari, Netherlands
Susan Chang, United States
Table 4: Storytelling in oral presentations
Marjolein Geurts, Netherlands
Table 5: Storytelling in clinical routine: Mastering difficult conversations with patients
Caroline Hertler, Switzerland
10:45-11:15 hrs | COFFEE BREAK
11:15-13:15 hrs
Michael Platten, Germany
President EANO
Aleksi Sedo, Czech Republic
President EANO Meeting 2025
Giuseppe Minniti, Italy
Chair EANO Scientific Committee
13:15-14:45 hrs | LUNCH BREAK
13:30-14:30 hrs
14:45-16:15 hrs
Chairs: tbc
KS02.1 Tailoring surgical resection of gliomas based upon clinical and molecular factors
Asgeir Jakola, Sweden
KS02.2 Stimulated Raman histology for rapid histopathological assessment and novel artificial intelligence approaches to optimize brain tumor surgery
Lisa Körner, Austria
KS02.3 The value of 5-ALA fluorescence for resection of meningiomas: data of a multicenter study
Walter Stummer, Germany
KS02.4 Intraoperative Diagnostics with Long-read Sequencing
Kirsten Göbel, Germany
Chairs: tbc
OS02.1 Precision Medicine in Neuroimaging - Radiomics and Beyond
tbc
OS02.2 Digital Twinning - the impact of glioma on the structure and functioning of brain networks
tbc
OS02.3 Imaging techniques to enhance understanding of the underlying biochemistry of diseases and improve patient health
Esin ÖZTÜRK IŞIK, Turkey
OS02.4 Future AI tools in response assessment
tbc
Chairs: tbc
OS03.1 Novel glioma mouse models
Daniel Schramek, Canada
OS03.2 Modelling host microenvironment in glioma
Claudia Pasquanlini, France
OS03.3 Modeling brain cancer with human pluripotent stem cells
Lena Kutscher, Germany
OS03.4 Allograft in utero electroporation mouse models of diffuse midline glioma
Esther Hulleman, Netherlands
16:15-16:30 hrs | BREAK
16:30-18:00 hrs
Chairs: tbc
JS04.1 Strategy to improve safety of RT in patients with adult-diffuse glioma: How can we implement the ESTRO-EANO guidelines
Maximilian Niyazi, Germany
JS04.2 Reirradiation of adult-type gliomas: ESTRO-EANO recommendations
tbc
JS04.3 Biology insights in radiation effects (with special regard to glioma RT)
Lara Barazzuol, Netherlands
JS04.4 Beyond the INDIGO trial: Which patients might benefit from IDH inhibitors?
Roberta Ruda, Italy
Chairs: tbc
JS05.1 Tumor-related epilepsy in patients with glioblastoma
Johan Pallud, France
JS05.2 Tumor-associated epilepsy – epilepsy surgery in neuro-oncology
Julia Onken, Germany
JS05.3 Targeting epilepsy and brain tumor growth - the PerSurge (NOA-30) phase II trial of perampanel in recurrent glioblastoma
tbc
JS05.4 Molecular neuropathology of tumor-associated epilepsy: insights into tumorigenesis and epileptogenesis
Eleonora Aronica, Netherlands
Chairs: tbc
Chairs: tbc